Patents by Inventor Sachiko Kajigaya
Sachiko Kajigaya has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10557118Abstract: Compositions and methods are provided for preventing or treating neoplastic disease in a mammalian subject. A composition is provided which comprises an enriched immune cell population reactive to a human endogenous retrovirus type E antigen on a tumor cell. A method of treating a neoplastic disease in a mammalian subject is provided which comprises administering to a mammalian subject a composition comprising an enriched immune cell population reactive to a human endogenous retrovirus type E antigen, in an amount effective to reduce or eliminate the neoplastic disease or to prevent its occurrence or recurrence.Type: GrantFiled: January 7, 2019Date of Patent: February 11, 2020Assignee: The Government of the United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Richard William Wyatt Childs, Yoshiyuki Takahashi, Sachiko Kajigaya, Nanae Harashima
-
Publication number: 20190127695Abstract: Compositions and methods are provided for preventing or treating neoplastic disease in a mammalian subject. A composition is provided which comprises an enriched immune cell population reactive to a human endogenous retrovirus type E antigen on a tumor cell. A method of treating a neoplastic disease in a mammalian subject is provided which comprises administering to a mammalian subject a composition comprising an enriched immune cell population reactive to a human endogenous retrovirus type E antigen, in an amount effective to reduce or eliminate the neoplastic disease or to prevent its occurrence or recurrence.Type: ApplicationFiled: January 7, 2019Publication date: May 2, 2019Applicant: The Government of the USA, as represented by the Secretary, Dept. of Health and Human ServicesInventors: Richard William Wyatt Childs, Yoshiyuki Takahashi, Sachiko Kajigaya, Nanae Harashima
-
Patent number: 10214726Abstract: Compositions and methods are provided for preventing or treating neoplastic disease in a mammalian subject. A composition is provided which comprises an enriched immune cell population reactive to a human endogenous retrovirus type E antigen on a tumor cell. A method of treating a neoplastic disease in a mammalian subject is provided which comprises administering to a mammalian subject a composition comprising an enriched immune cell population reactive to a human endogenous retrovirus type E antigen, in an amount effective to reduce or eliminate the neoplastic disease or to prevent its occurrence or recurrence.Type: GrantFiled: November 22, 2017Date of Patent: February 26, 2019Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Richard William Wyatt Childs, Yoshiyuki Takahashi, Sachiko Kajigaya, Nanae Harashima
-
Publication number: 20180112178Abstract: Compositions and methods are provided for preventing or treating neoplastic disease in a mammalian subject. A composition is provided which comprises an enriched immune cell population reactive to a human endogenous retrovirus type E antigen on a tumor cell. A method of treating a neoplastic disease in a mammalian subject is provided which comprises administering to a mammalian subject a composition comprising an enriched immune cell population reactive to a human endogenous retrovirus type E antigen, in an amount effective to reduce or eliminate the neoplastic disease or to prevent its occurrence or recurrence.Type: ApplicationFiled: November 22, 2017Publication date: April 26, 2018Applicant: The Government of the USA, as represented by the Secretary, Dept. of Health and Human ServicesInventors: Richard William Wyatt Childs, Yoshiyuki Takahashi, Sachiko Kajigaya, Nanae Harashima
-
Patent number: 9856453Abstract: Compositions and methods are provided for preventing or treating neoplastic disease in a mammalian subject. A composition is provided which comprises an enriched immune cell population reactive to a human endogenous retrovirus type E antigen on a tumor cell. A method of treating a neoplastic disease in a mammalian subject is provided which comprises administering to a mammalian subject a composition comprising an enriched immune cell population reactive to a human endogenous retrovirus type E antigen, in an amount effective to reduce or eliminate the neoplastic disease or to prevent its occurrence or recurrence.Type: GrantFiled: November 20, 2014Date of Patent: January 2, 2018Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Richard William Wyatt Childs, Yoshiyuki Takahashi, Sachiko Kajigaya, Nanae Harashima
-
Publication number: 20150152384Abstract: Compositions and methods are provided for preventing or treating neoplastic disease in a mammalian subject. A composition is provided which comprises an enriched immune cell population reactive to a human endogenous retrovirus type E antigen on a tumor cell. A method of treating a neoplastic disease in a mammalian subject is provided which comprises administering to a mammalian subject a composition comprising an enriched immune cell population reactive to a human endogenous retrovirus type E antigen, in an amount effective to reduce or eliminate the neoplastic disease or to prevent its occurrence or recurrence.Type: ApplicationFiled: November 20, 2014Publication date: June 4, 2015Inventors: RICHARD WILLIAM WYATT CHILDS, YOSHIYUKI TAKAHASHI, SACHIKO KAJIGAYA, NANAE HARASHIMA
-
Patent number: 8921050Abstract: Compositions and methods are provided for preventing or treating neoplastic disease in a mammalian subject. A composition is provided which comprises an enriched immune cell population reactive to a human endogenous retrovirus type E antigen on a tumor cell. A method of treating a neoplastic disease in a mammalian subject is provided which comprises administering to a mammalian subject a composition comprising an enriched immune cell population reactive to a human endogenous retrovirus type E antigen, in an amount effective to reduce or eliminate the neoplastic disease or to prevent its occurrence or recurrence.Type: GrantFiled: March 16, 2007Date of Patent: December 30, 2014Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Richard William Wyatt Childs, Yoshiyuki Takahashi, Sachiko Kajigaya, Nanae Harashima
-
Publication number: 20130052226Abstract: The invention provides a codon-optimized parvovirus polynucleotide composition and methods of expressing this polynucleotide in a variety of mammalian cells, including non-erythroid progenitor cells, to produce immunogenic compositions.Type: ApplicationFiled: February 9, 2011Publication date: February 28, 2013Applicant: The Government of the USA, as represented by the Secretary, Department of Health & Human ServicesInventors: Ning Zhi, Neal S. Young, Sachiko Kajigaya
-
Publication number: 20070259370Abstract: Methods are provided herein for measuring the mutational frequency of a DNA molecule in cells, for example stem cells or hematopoietic cells such as CD34+ cells or granulocytes. The method includes sequencing corresponding regions of mtDNA from a set of hematopoietic cells, or a set of clonal populations of hematopoietic cells, and comparing the sequence of the corresponding regions of mtDNA from the cells, or clonal populations of cells. The method also includes the comparison of mtDNA sequences with genomic DNA sequences. Also provided are methods for screening for an agent that has a mutagenic effect on a cell. The method includes contacting, or treating, clonal populations of cells with an agent and comparing the sequence of the mtDNA obtained from the treated clonal populations of cells, with the sequence of the corresponding region of mtDNA obtained from a control clonal populations of cells.Type: ApplicationFiled: June 28, 2007Publication date: November 8, 2007Inventors: Neal Young, Sachiko Kajigaya
-
Patent number: 7255993Abstract: Methods are provided herein for measuring the mutational frequency of a DNA molecule in cells, for example stem cells or hematopoietic cells such as CD34+ cells or granulocytes. The method includes sequencing corresponding regions of mtDNA from a set of hematopoietic cells, or a set of clonal populations of hematopoietic cells, and comparing the sequence of the corresponding regions of mtDNA from the cells, or clonal populations of cells. The method also includes the comparison of mtDNA sequences with genomic DNA sequences. Also provided are methods for screening for an agent that has a mutagenic effect on a cell. The method includes contacting, or treating, clonal populations of cells with an agent and comparing the sequence of the mtDNA obtained from the treated clonal populations of cells, with the sequence of the corresponding region of mtDNA obtained from a control clonal populations of cells.Type: GrantFiled: November 6, 2003Date of Patent: August 14, 2007Assignee: The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Neal S. Young, Sachiko Kajigaya
-
Publication number: 20030147919Abstract: The present invention relates to a method of producing non-infections parvovirus capsids and to diagnostic assays and vaccines utilizing same. The invention further relates to recombinant baculoviruses encoding parvovirus structural proteins and host cells infected therewith. The invention also relates to a method of packaging and delivering genetic information utilizing the noninfectious capsids.Type: ApplicationFiled: February 13, 2003Publication date: August 7, 2003Applicant: The United States of America, represented by the Secretary, Department of Health and Human ServicesInventors: Neal S. Young, Sachiko Kajigaya, Shimada Takashi
-
Patent number: 6558676Abstract: The present invention relates to a method of producing non-infections parvovirus capsids and to diagnostic assays and vaccines utilizing same. The invention further relates to recombinant baculoviruses encoding parvovirus structural proteins and host cells infected therewith. The invention also relates to a method of packaging and delivering genetic information utilizing the noninfectious capsids.Type: GrantFiled: July 6, 2000Date of Patent: May 6, 2003Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Neal S. Young, Sachiko Kajigaya, Shimada Takashi
-
Patent number: 6132732Abstract: The present invention relates to a method of producing non-infections parvovirus capsids and to diagnostic assays and vaccines utilizing same. The invention further relates to recombinant baculoviruses encoding parvovirus structural proteins and host cells infected therewith. The invention also relates to a method of packaging and delivering genetic information utilizing the noninfectious capsids.Type: GrantFiled: March 21, 1995Date of Patent: October 17, 2000Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Neal S. Young, Sachiko Kajigaya, Shimada Takashi
-
Patent number: 6001371Abstract: The present invention relates to a method of producing non-infections parvovirus capsids and to diagnostic assays and vaccines utilizing same. The invention further relates to recombinant baculoviruses encoding parvovirus structural proteins and host cells infected therewith. The invention also relates to a method of packaging and delivering genetic information utilizing the noninfectious capsids.Type: GrantFiled: June 5, 1995Date of Patent: December 14, 1999Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Neal S. Young, Sachiko Kajigaya, Takashi Shimada
-
Patent number: 5916563Abstract: The present invention relates to a parvovirus protein presenting capsid. Protein presenting capsid can be made by substituting nonparvovirus proteins, such as antigenic epitopes, ligands, enzymes, or peptide sequences, for the unique region of the parvovirus minor structural protein (e.g. VP1). Small regions of VP2 can also be replaced. Normal VP2 can be added to enhance capsid formation.Type: GrantFiled: June 3, 1994Date of Patent: June 29, 1999Assignee: United States of AmericaInventors: Neal S. Young, Sachiko Kajigaya, Shimada Takashi
-
Patent number: 5827647Abstract: The present invention relates to a method of producing non-infectious-parvovirus capsids and to diagnostic assays and vaccines utilizing same. The invention further relates to recombinant baculoviruses encoding parvovirus structural proteins and host cells infected therewith. The invention also relates to a method of packaging and delivering genetic information utilizing the noninfectious capsids.Type: GrantFiled: June 5, 1995Date of Patent: October 27, 1998Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Neal S. Young, Sachiko Kajigaya, Takashi Shimada
-
Patent number: 5508186Abstract: The present invention relates to a method of producing non-infections parvovirus capsids and to diagnostic assays and vaccines utilizing same. The invention further relates to recombinant baculoviruses encoding parvovirus structural proteins and host cells infected therewith. The invention also relates to a method of packaging and delivering genetic information utilizing the noninfectious capsids.Type: GrantFiled: November 14, 1990Date of Patent: April 16, 1996Assignee: The United States of America as represented by the Secretary of Health and Human ServicesInventors: Neal S. Young, Sachiko Kajigaya, Takashi Shimada